Cargando…

13. The Efficacy and Effectiveness of Pneumococcal Vaccines against Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis

BACKGROUND: Two pneumococcal vaccines are currently recommended for use in U.S. adults: 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13). Recommendations for adult PCV13 use were supported by a large randomized-controlled trial (RCT) demonst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Childs, Lana, Kobayashi, Miwako, Farrar, Jennifer Loo, Pilishvili, Tamara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644232/ http://dx.doi.org/10.1093/ofid/ofab466.215

Ejemplares similares

Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults
por: Farrar, Jennifer L., et al.
Publicado: (2023)

20. Cost-Effectiveness of Implementing 13-Valent Pneumococcal Conjugate Vaccine (Pcv13) for Adults Aged ≥19 Years with Underlying Conditions
por: Kobayashi, Miwako, et al.
Publicado: (2020)

1474. Impact of 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Non-bacteremic Pneumococcal Pneumonia (NBPP) among Adults in the United States, 2013-2017
por: Gierke, Ryan, et al.
Publicado: (2020)

Changes in invasive pneumococcal disease among adults living with HIV following introduction of 13-valent pneumococcal conjugate vaccine, 2008–2014
por: Kobayashi, Miwako, et al.
Publicado: (2017)

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
por: Kobayashi, Miwako, et al.
Publicado: (2022)

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
por: Matanock, Almea, et al.
Publicado: (2019)

180. Impact of Pneumococcal Conjugative Vaccine on Antibiotic Resistant Invasive Pneumococcal Disease in the United States
por: Bajema, Kristina, et al.
Publicado: (2020)

70. Changes in Invasive Pneumococcal Disease among Adults Living with HIV Following Introduction of 13-Valent Pneumococcal Conjugate Vaccine, 2008–2018
por: Matanock, Almea, et al.
Publicado: (2021)

2718. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in US Adults Hospitalized with Pneumonia, 2014–2017
por: Lessa, Fernanda C, et al.
Publicado: (2019)

1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States
por: Pilishvili, Tamara, et al.
Publicado: (2020)

1718. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: an indirect cohort study
por: Andrejko, Kristin, et al.
Publicado: (2023)

Direct and Indirect Impact of 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD) Among Children and Adults in the U.S.
por: Pilishvili, Tamara, et al.
Publicado: (2017)

1373. Vaccine Effectiveness and Pneumococcal Serotypes in Pediatric Otitis Media in the Era of Routine 13-valent Pneumococcal Vaccination in the United States
por: Hulten, Kristina G, et al.
Publicado: (2020)

151. Evaluation of Pneumococcal Vaccine Effectiveness Against Invasive Pneumococcal Disease Among US Medicare Beneficiaries ≥65 Years Old
por: Pilishvili, Tamara, et al.
Publicado: (2018)

2711. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Older Adults
por: Lewis, Ned, et al.
Publicado: (2019)

1480. Incidence of Non-Invasive Pneumococcal Pneumonia in Children in the United States before and after Introduction Pneumococcal Conjugate Vaccines (PCV7 and PCV13) during 1998-2018
por: Hu, Tianyan, et al.
Publicado: (2020)

1436. Risk Factors for Invasive Pneumococcal Disease in Adults ≥65 Years Old Following Pneumococcal Conjugate Vaccine Recommendation
por: Almendares, Olivia M, et al.
Publicado: (2018)

1461. Non-Invasive Pneumococcal Pneumonia in the United States, 2013–2014
por: Matanock, Almea, et al.
Publicado: (2018)

1430. Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease
por: Yildirim, Inci, et al.
Publicado: (2018)

2717. The Impact of Pneumococcal Conjugate Vaccine in Nonbacteremic Pneumococcal Pneumonia Among Cancer Patients
por: Lee, Yeon Joo, et al.
Publicado: (2019)

176. Selected Impact of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD) at Eight Children’s Hospitals in the United States. 2014–2019
por: Kaplan, Sheldon L, et al.
Publicado: (2020)

Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years
por: Black, Carla L., et al.
Publicado: (2017)

596 Potential public health impact of 13-valent pneumococcal conjugate vaccine use among US adults 65 years of age or older
por: Pilishvili, Tamara, et al.
Publicado: (2014)

Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023
por: Kobayashi, Miwako, et al.
Publicado: (2023)

295. Is Herd Immunity from Pneumococcal Conjugate Vaccines Changing the Clinical Features of Invasive Pneumococcal Disease in Adults?
por: McGeer, Allison, et al.
Publicado: (2020)

2555. Predicting Risk of Breakthrough Invasive Pneumococcal Disease in Children After 13-Valent Pneumococcal Conjugate Vaccination
por: Yildirim, Melike, et al.
Publicado: (2018)

2707. Non 13-Valent Pneumococcal Conjugate Vaccine Serotypes Predominate as Causes of Pneumococcal Otitis Media in Children
por: Hulten, Kristina G, et al.
Publicado: (2019)

P18 Value of pneumococcal PCR in respiratory samples for exclusion of pneumococcal pneumonia
por: Van Herendael, Bruno, et al.
Publicado: (2023)

1180. Comparing Changes in Pneumococcal Meningitis Incidence to all Invasive Pneumococcal Disease Following Introduction of PCV10 and PCV13: The PSERENADE Project
por: Yang, Yangyupei, et al.
Publicado: (2021)

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
por: Tomczyk, Sara, et al.
Publicado: (2014)

1439. The Cost-Effectiveness of Vaccinating Adults at Increased Risk of Pneumococcal Disease Against Pneumococcal Disease in The Netherlands
por: Rozenbaum, Mark
Publicado: (2018)

647 Impact of 13-valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in the United States
por: Kim, Lindsay, et al.
Publicado: (2014)

1445. Impact of 10-Valent Pneumococcal Conjugate Vaccine Introduction on Pneumococcal Carriage and Antibiotic Susceptibility Patterns Among Children Aged <5 Years and Adults with HIV Infection, Kenya 2009–2013
por: Kobayashi, Miwako, et al.
Publicado: (2018)

1475. Impact of a Routine Infant PCV Program on the Serotype Distribution of Episodes of Invasive Pneumococcal Disease (IPD) and Non-bacteremic Pneumococcal Pneumonia in Adults
por: McGeer, Allison
Publicado: (2020)

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
por: Bennett, Nancy M., et al.
Publicado: (2013)

Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic
por: Tomczyk, Sara, et al.
Publicado: (2018)

Efficacy of Influenza and Pneumococcal Vaccination in Preventing COPD Exacerbation
por: Haque, Azharul, et al.
Publicado: (2017)

2701. The Impact of Infant 13-valent Conjugate Pneumococcal Vaccination Program on Invasive Pneumococcal Disease in Children in British Columbia, Canada
por: Vadlamudi, Nirma K, et al.
Publicado: (2019)

301. Detection of Pneumococcal Pneumonia During SARS-CoV-2 Infection
por: Watkins, Anne, et al.
Publicado: (2021)

2716. Persistence of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Serotypes in Invasive Pneumococcal Disease in Adults in Southern Ontario Canada Despite Routine Pediatric Vaccination
por: McGeer, Allison, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r2fdcifdhnb05lvn2tsn2bho4r